TickerStat.comEloxx Pharmaceuticals annual asset turnover
2012
2013
2014
2022
2023
2024
2025
Eloxx Pharmaceuticals Asset Turnover Growth & History (ELOX)
Eloxx Pharmaceuticals's asset turnover was 0.00 for fiscal 2025.
View full Eloxx Pharmaceuticals company overviewEloxx Pharmaceuticals annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.00 | −2.71 | — |
| 2024 | 2024-12-31 | 2.71 | 2.71 | — |
| 2023 | 2023-12-31 | 0.00 | 0.00 | — |
| 2022 | 2022-12-31 | 0.00 | — | — |
| 2014 | 2014-06-30 | 0.01 | 0.01 | +710.01% |
| 2013 | 2013-06-30 | 0.00 | −0.02 | −95.67% |
| 2012 | 2012-06-30 | 0.03 | — | — |
Eloxx Pharmaceuticals asset turnover trends
Between the periods ended 2012-06-30 and 2025-12-31, Eloxx Pharmaceuticals's asset turnover decreased from 0.03 to 0.00, a change of −0.03.
About the metric
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
Calculation and source
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eloxx Pharmaceuticals source filings ↗Community posts
Eloxx doses first patients in mid-stage Alport syndrome trial
Eloxx Pharmaceuticals ($ELOX) dosed the first two patients in its Phase 2b EXACT study of exaluren for Alport syndrome caused by nonsense mutations. The trial plans to enroll 24 patients with relevant mutations in the COL4A3, COL4A4 or COL4 ...